Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Phenomix's Series B Gets $40M For Diabetes, Arthritis Programs

May 25, 2005

By Jennifer Boggs

Phenomix's Series B Gets $40M For Diabetes, Arthritis Programs

May 25, 2005

By Jennifer Boggs

Enanta In-Licenses Chiron's HCV Protease Inhibitor Group

May 20, 2005

By Jennifer Boggs

Enanta In-Licenses Chiron's HCV Protease Inhibitor Group

May 20, 2005

By Jennifer Boggs

Zelos' Series B Round Nets $42M For PTH Drug Pipeline

May 19, 2005

By Jennifer Boggs

Zelos Therapeutics Inc. raised $42.5 million in a Series B round to fund clinical trials of its next-generation parathyroid hormone (PTH) analogue in four indications. (BioWorld Today)

Zelos' Series B Round Nets $42M For PTH Drug Pipeline

May 19, 2005

By Jennifer Boggs

Zelos Therapeutics Inc. raised $42.5 million in a Series B round to fund clinical trials of its next-generation parathyroid hormone (PTH) analogue in four indications. (BioWorld Today)

Licensing Deal Gives Spectrum Radiation Adjunct For Cancer

May 18, 2005

By Jennifer Boggs

Licensing Deal Gives Spectrum Radiation Adjunct For Cancer

May 18, 2005

By Jennifer Boggs

Reverse Merger Gives Rexahn Listing On OTC Bulletin Board

May 17, 2005

By Jennifer Boggs

Xcyte Calls Off Cancer Trial, Shifts Focus To HIV Program

May 17, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...